8-K: Anika Therapeutics Reaches Cooperation Agreement with Caligan Partners, Appoints New Directors and Announces $40 Million Share Buyback

Anika Therapeutics has entered into a cooperation agreement with Caligan Partners, resulting in the appointment of two new board members and a $40 million share repurchase program.

Summary

• Anika Therapeutics has reached a cooperation agreement with Caligan Partners, which includes the appointment of William Jellison and Joseph Capper as independent directors.
• The board size will increase to ten members temporarily, then reduce to nine after the 2024 annual meeting.
• A new share repurchase program of $40 million has been authorized, with $15 million to be executed through a 10b5-1 plan by June 30, 2025, and the remainder in the open market by June 30, 2026.
• The share repurchase program may increase by 50% of positive free cash flow between July 1, 2024 and June 30, 2025, but the company's cash balance must remain above $45 million after the buyback and anticipated expenses.
• Caligan Partners has agreed to certain voting commitments and standstill provisions during the defined period.
• The new directors will serve on the Capital Allocation Committee, which will consist of five members.

Sentiment

Score: 7

Explanation: The document is generally positive, with the resolution of a potential proxy fight, the addition of experienced directors, and a share repurchase program. However, there are some risks and limitations associated with the share repurchase program and the company's future performance.

Positives

• The addition of William Jellison and Joseph Capper brings significant MedTech experience to the board.
• The $40 million share repurchase program signals a commitment to returning capital to shareholders.
• The potential increase in the share repurchase program based on positive free cash flow provides an additional benefit to shareholders.
• The cooperation agreement with Caligan Partners resolves a potential proxy contest and aligns interests.
• The company is on track to generate $25-$30 million in adjusted EBITDA for 2024, up over 75% at the midpoint from 2023.

Negatives

• The share repurchase program is subject to market conditions and legal requirements.
• The company's cash balance must remain above $45 million after the buyback and anticipated expenses, which could limit the amount of shares repurchased.
• The standstill agreement limits Caligan Partners' ability to influence the company during the defined period.

Risks

• The company's ability to execute the share repurchase program is subject to market conditions and legal requirements.
• The company's cash balance must remain above $45 million after the buyback and anticipated expenses, which could limit the amount of shares repurchased.
• The company's future performance is subject to various risks, including clinical trial outcomes, regulatory approvals, and market conditions.
• The company's ability to achieve its growth targets is subject to various factors, including the strength of the economies in which the company operates.

Future Outlook

The company expects to continue to return capital to stockholders and is focused on optimizing the business to maximize value for all stockholders. They are on track to generate $25-$30 million in adjusted EBITDA for 2024.

Management Comments

• Cheryl R. Blanchard, Ph.D., Anika's President and CEO, stated that they are pleased to welcome the new directors and that the company is seeing the results of cost reduction initiatives.
• John B. Henneman, III, Anika's Chair of the Board, said that the company is committed to a strategy of sustainable profitability and enhancing operational and financial performance.
• David Johnson, Managing Partner of Caligan, expressed satisfaction with the resolution and believes the new directors will add value to the board.

Industry Context

This announcement reflects a trend of activist investors engaging with companies to drive change and enhance shareholder value. The appointment of experienced MedTech executives to the board and the implementation of a share repurchase program are common strategies to improve financial performance and investor confidence.

Comparison to Industry Standards

• The appointment of experienced executives like Joseph Capper (CEO of MIMEDX) and William Jellison (former CFO of Stryker) is consistent with industry best practices for board composition, as these individuals bring deep operational and financial expertise.
• The $40 million share repurchase program is a common method for returning capital to shareholders, similar to programs implemented by other companies in the medical device sector such as Zimmer Biomet and Medtronic.
• The cooperation agreement with Caligan Partners is similar to agreements reached between other companies and activist investors, such as the agreement between Masimo and Politan Capital, which often include board representation and strategic changes.
• The company's focus on achieving $25-$30 million in adjusted EBITDA for 2024 is a key metric that investors will compare to peers like Orthofix and NuVasive, which also focus on profitability and growth.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the potential for increased value.
• Employees may experience a more stable and focused company with the new board members and strategic direction.
• Customers may benefit from the company's focus on core strengths and improved financial performance.
• Suppliers may experience more consistent business with a financially stable company.
• Creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company will initiate the $15 million share repurchase through a 10b5-1 plan by May 31, 2024.
• The company will complete the remaining share repurchase in the open market by June 30, 2026.
• The company will hold its 2024 Annual Meeting of Stockholders.
• The board size will reduce to nine directors after the 2024 Annual Meeting.

Key Dates

Keywords

share repurchase, board of directors, cooperation agreement, Caligan Partners, William Jellison, Joseph Capper, capital allocation, MedTech, corporate governance, standstill agreement